ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0020

CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis

Lance Murphy1, Kevin Burt2, Vu Nguyen3, Baofeng Hu2, Robert Mauck3 and Carla Scanzello2, 1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia

Meeting: ACR Convergence 2024

Keywords: interferon, Osteoarthritis, osteoclast

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that CD14-deficient mice show significantly less OA-associated subchondral bone (Sambamurthy N, 2018). CD14 is a GPI-anchored surface protein and co-receptor for several inflammatory TLRs, and is highly expressed in myeloid cells including osteoclast precursors (Zanoni, I 2013; Xue, J 2020). TLR activation can both activate and inhibit osteoclastogenic potential. Therefore, using a CD14-deficient mouse model we hypothesized that inhibitory effects of TLR-stimuli on osteoclast differentiation would be ameliorated in CD14 deficient cells.

Methods: Cell isolation and culture (n=3-5): Bone Marrow was isolated from femurs and tibiae of skeletally mature (10-12 wk old) C57BL/6 (WT) and CD14-deficient mice. Following 24 hr suspension culture, cells were cultured in complete aMEM with 30 ng/mL M-CSF, for 5 days to expand osteoclast precursors (macrophages). Cells were passaged on day 6 and cultured (24 well plate, 50,000 cells/well) in the presence or absence of RANKL (100 ng/mL). In a separate study, cells were stimulated with a TLR4-stimulus (LPS, 1 ng/mL), soluble CD14 (1 µg/mL), and a TLR4-inhibitor (CLI-095, 1 µg/mL), or an Anti-IFNAR1 antibody (1 ug/mL).

Osteoclast staining and image analysis: Cells were stained for Tartrate-resistant acid phosphatase (TRAP) on days 3 and 4 after addition of RANKL. Cells were imaged at 10x (3 images/well over 4 wells per timepoint) and quantified (%area covered) using ImageJ and CellProfiler. Number of osteoclasts (cells with >3 nuclei) per 10X field was also quantitated. Multiple unpaired t-test were performed with Holm-Sidak correction.

Results: CD14-deficient mice possessed increase osteoclast area at baseline and post-injury (Fig. 1A,B). Cells showed more rapid differentiation than WT cells at baseline (Fig. 2). Area of the plate covered by osteoclasts (Fig. 2B) were higher in CD14-deficient cells on day 3 and day 4. TLR4-stimuli: With LPS stimulation, CD14-deficient cells differentiated more quickly compared to WT at day 3 (p< 0.001) (Fig. 3G). LPS stimulation led to a 77% decrease of osteoclastogenesis in the WT cells, but only a 7.5% decrease in osteoclastogenesis on the CD14-deficient cells (Figure 2G, 3G) Addition of CLI-095 mitigated some inhibitory effects of LPS in WT, but had a synergistic effect on CD14-deficient cells (Fig 3H). The addition of sCD14 inhibited osteoclastogenesis in the CD14-deficient group, both with and without LPS. RNA sequencing was completed on osteoclasts on day 4 and showed decreased Type I Interferon signaling. At baseline, the Anti-IFNAR antibody mitigated the difference between WT and CD14-deficient mice. However, this was not shown with LPS addition.

Conclusion: Our results show that at baseline, CD14-deficient osteoclasts precursors differentiate more quickly than WT cells likely due to Type I Interferon singaling. Further, during TLR4 stimulation studies, CD14-deficient cells were protected from LPS-TLR4 mediated inhibition of osteoclastogenesis, compared to WT cells, likely due to decreased signaling through the MyD88-dependent pathway.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Murphy: None; K. Burt: None; V. Nguyen: None; B. Hu: None; R. Mauck: None; C. Scanzello: None.

To cite this abstract in AMA style:

Murphy L, Burt K, Nguyen V, Hu B, Mauck R, Scanzello C. CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cd14-deficiency-protects-against-tlr4-lps-mediated-inhibition-of-osteoclastogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd14-deficiency-protects-against-tlr4-lps-mediated-inhibition-of-osteoclastogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology